Payment overview · 2025
General Payments
$284.71
17 reported records · 8 companies
Healthcare provider profile · identity verified
Johnathan K Leck, MD
Allopathic & Osteopathic Physicians|Family Medicine · ATCHISON, KS · NPI 1720428246
Verified facts
What the public records show
CMS Open Payments records show Johnathan K Leck, MD received $284.71 in general payments during 2025 across 17 reported records.
ABBVIE INC. accounted for 26.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Enbrel by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 376 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $74.25 | 26.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $56.15 | 19.7% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.79 | 17.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.78 | 13.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.49 | 7.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.06 | 5.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.94 | 5.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.25 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $284.71 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $74.25 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.82 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $49.79 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $49.79 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $49.79 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $41.47 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.47 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 82 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
161 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
376 | 43 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 765 | 121 |
| Potassium Chloride | Potassium Chloride | 590 | 106 |
| Furosemide | Furosemide | 572 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 539 | 101 |
| Gabapentin | Gabapentin | 514 | 90 |
| Atorvastatin Calcium | Atorvastatin Calcium | 486 | 113 |
| Losartan Potassium | Losartan Potassium | 479 | 103 |
| Omeprazole | Omeprazole | 467 | 86 |
| Lisinopril | Lisinopril | 439 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 428 | 102 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 406 | 87 |
| Eliquis | Apixaban | 376 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 354 | 72 |
| Escitalopram Oxalate | Escitalopram Oxalate | 346 | 67 |
| Alprazolam | Alprazolam | 310 | 57 |
| Tramadol Hcl | Tramadol Hcl | 261 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 254 | 56 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 254 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 253 | 39 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 240 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 238 | 53 |
| Alendronate Sodium | Alendronate Sodium | 237 | 51 |
| Trazodone Hcl | Trazodone Hcl | 210 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 206 | 43 |
| Allopurinol | Allopurinol | 205 | 42 |
| Montelukast Sodium | Montelukast Sodium | 200 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 197 | 45 |
| Metformin Hcl | Metformin Hcl | 194 | 43 |
| Torsemide | Torsemide | 187 | 34 |
| Simvastatin | Simvastatin | 185 | 39 |
| Glipizide Er | Glipizide | 176 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 164 | 34 |
| Myrbetriq | Mirabegron | 161 | 12 |
| Carvedilol | Carvedilol | 158 | 35 |
| Memantine Hcl | Memantine Hcl | 151 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 150 | 39 |
| Baclofen | Baclofen | 148 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 146 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 144 | 26 |
| Sertraline Hcl | Sertraline Hcl | 142 | 27 |
| Cefdinir | Cefdinir | 132 | 110 |
| Quetiapine Fumarate | Quetiapine Fumarate | 128 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 125 | 28 |
| Meloxicam | Meloxicam | 121 | 26 |
| Famotidine | Famotidine | 116 | 30 |
| Celecoxib | Celecoxib | 115 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 113 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 22 |
| Methylprednisolone | Methylprednisolone | 107 | 93 |
| Mirtazapine | Mirtazapine | 105 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 105 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 105 | 18 |
| Fentanyl | Fentanyl | 103 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 102 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 29 |
| Atenolol | Atenolol | 100 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 100 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 21 |
| Bupropion Xl | Bupropion Hcl | 96 | 20 |
| Ondansetron Odt | Ondansetron | 94 | 47 |
| Ezetimibe | Ezetimibe | 90 | 28 |
| Donepezil Hcl | Donepezil Hcl | 88 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 84 | 11 |
| Ozempic | Semaglutide | 84 | 18 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 82 | 71 |
| Jardiance | Empagliflozin | 82 | 14 |
| Azithromycin | Azithromycin | 80 | 63 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 41 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 76 | 13 |
| Prednisone | Prednisone | 75 | 44 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 73 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 70 | 13 |
| Clonazepam | Clonazepam | 68 | 14 |
| Januvia | Sitagliptin Phosphate | 66 | suppressed |
| Diazepam | Diazepam | 64 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 62 | 12 |
| Buspirone Hcl | Buspirone Hcl | 61 | 12 |
| Pregabalin | Pregabalin | 59 | 14 |
| Spironolactone | Spironolactone | 59 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 59 | 45 |
| Sucralfate | Sucralfate | 57 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | suppressed |
| Glimepiride | Glimepiride | 56 | 11 |
| Metformin Hcl Er | Metformin Hcl | 56 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 55 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 54 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 32 |
| Temazepam | Temazepam | 54 | suppressed |
| Lorazepam | Lorazepam | 53 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | suppressed |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Lovastatin | Lovastatin | 51 | suppressed |
| Nystatin | Nystatin | 51 | 26 |
| Finasteride | Finasteride | 50 | 14 |
| Glipizide | Glipizide | 49 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 48 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 47 | suppressed |
| Lactulose | Lactulose | 46 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 46 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 16 |
| Colchicine | Colchicine | 44 | 13 |
| Klayesta | Nystatin | 43 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 43 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | 11 |
| Latanoprost | Latanoprost | 42 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 40 | suppressed |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Topiramate | Topiramate | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 11 |
| Fluconazole | Fluconazole | 38 | 29 |
| Testosterone Cypionate | Testosterone Cypionate | 36 | suppressed |
| Naproxen | Naproxen | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Primidone | Primidone | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 22 |
| Meclizine Hcl | Meclizine Hcl | 31 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 26 |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Sotalol | Sotalol Hcl | 29 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 29 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 22 |
| Linzess | Linaclotide | 26 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Metolazone | Metolazone | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 25 | suppressed |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Auryxia | Ferric Citrate | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Methimazole | Methimazole | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 20 | 17 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Carisoprodol | Carisoprodol | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Rivastigmine | Rivastigmine | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 16 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 11 |
| Restasis Multidose | Cyclosporine | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Flavoxate Hcl | Flavoxate Hcl | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Enbrel | Etanercept | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 11 | suppressed |
| Trospium Chloride | Trospium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $284.71 · 17 records | ABBVIE INC. | ABRYSVO, Auvelity, COMIRNATY, EVENITY, JARDIANCE, MOUNJARO, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, UBRELVY, Veozah, XIFAXAN, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error